07/06/2026
AI Designed a Vaccine Against COVID - A Cure for Future Pandemics is Already Here?
Scientists from the University of Cambridge and the company DIOSynVax have conducted the first human trial of a vaccine whose core component was designed entirely by artificial intelligence, not by humans. Thirty-nine healthy volunteers participated in the study. The vaccine proved safe and produced no significant side effects. But the more remarkable aspect is this: it was not developed against a single specific virus, but against an entire family of coronaviruses - including SARS-CoV-2, the pathogen behind the COVID-19 pandemic.
A conventional vaccine works straightforwardly: it contains a fragment of a real virus so that the immune system can learn to recognize and fight it in advance. This project took a different approach. Instead of extracting a fragment from a known virus, the team fed a machine learning algorithm the full body of genomic data collected over years by global viral surveillance programs. The algorithm then constructed a synthetic target - a so-called "superantigen" - encoding features shared across the entire coronavirus family, including variants that do not yet exist. The results were published in the Journal of Infection.
Why the added complexity? The problem with conventional vaccines is that they are always playing catch-up: viruses mutate, new strains emerge, and vaccines must be reformulated almost annually. The project's scientific director, Jonathan Heeney, compared this to a dog chasing its own tail. An AI-designed superantigen vaccine is intended to break that cycle. In the trial, it triggered an immune response not only against SARS-CoV-2 and its older relative SARS, but also against related bat coronaviruses that have not yet made the jump to humans. The goal is to prepare for the next pandemic before it begins.
The vaccine itself is a DNA-based preparation delivered needle-free - injected as a fine jet through the skin, which also addresses the concern of needle-averse patients. The project was funded by UK Research and Innovation through Innovate UK.
It is important to note that this is only the earliest phase of clinical testing, conducted on a small group primarily to assess safety. A second phase involving a larger and more diverse cohort is next, where the effectiveness of the protection will need to be confirmed. The authors also believe the same approach could be applied to other virus families, such as Ebola or influenza.
*Source: https://www.cam.ac.uk/research/news/new-universal-vaccine-technology-could-protect-us-from-future-virus-outbreaks